Enveric's EB-003 Shows Dual 5-HT2A Signaling With β-Arrestin Bias
Enveric Biosciences reports that EB-003 engages both Gq and β-arrestin pathways at the 5-HT2A receptor, showing a modest β-arrestin bias relative to serotonin. The lead neuroplastogen candidate continues IND-enabling studies with proprietary BRET assays to support its non-hallucinogenic treatment potential.
1. BRET Assay Data
Enveric Biosciences developed proprietary bioluminescence resonance energy transfer (BRET) assays to measure EB-003 engagement at the 5-HT2A receptor, demonstrating activation of both Gq- and β-arrestin–mediated signaling.
2. Signaling Bias Analysis
Comparative analysis shows EB-003 exhibits a modest preference toward β-arrestin signaling over Gq relative to serotonin, suggesting potential separation of antidepressant benefits from hallucinogenic pathways.
3. Development and Next Steps
EB-003 remains in IND-enabling studies with planned expansion of BRET testing to include Gi pathway characterization ahead of clinical trials to ensure a well-defined mechanism and potential at-home administration.